Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.

CONCLUSIONS: Most patients received guideline-concordant AST, except for those with the HR+/HER2+ subtype. Patients receiving guideline-adherent adjuvant therapy had better survival outcomes across all breast cancer subtypes. PMID: 31200362 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31200362?dopt=Abstract

Source: Journal of the National Comprehensive Cancer Network : JNCCN - June 15, 2019 Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research